OBJECTIVE AND DESIGN: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression. METHODS: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined. RESULTS: CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomatic and non-treated, we observed a correlation between CCR5 density on HLA-DR(-)CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002). CONCLUSION: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density.
OBJECTIVE AND DESIGN: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression. METHODS: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined. RESULTS:CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomatic and non-treated, we observed a correlation between CCR5 density on HLA-DR(-)CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002). CONCLUSION: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density.
Authors: S T Sadiq; J McSorley; A J Copas; J Bennett; S J Edwards; S Kaye; S Kirk; P French; I V D Weller Journal: Sex Transm Infect Date: 2005-10 Impact factor: 3.519
Authors: Amie L Meditz; Joy M Folkvord; Ngan H Lyle; Kristina Searls; Yolanda S Lie; Eoin P Coakley; Martin McCarter; Samantha Mawhinney; Elizabeth Connick Journal: J Infect Dis Date: 2013-10-31 Impact factor: 5.226
Authors: Amie L Meditz; Michelle K Haas; Joy M Folkvord; Kelsey Melander; Russ Young; Martin McCarter; Samantha Mawhinney; Thomas B Campbell; Yolanda Lie; Eoin Coakley; David N Levy; Elizabeth Connick Journal: J Virol Date: 2011-08-03 Impact factor: 5.103
Authors: F Nicoletti; C Lapenta; C Lamenta; S Donati; M Spada; A Ranazzi; B Cacopardo; K Mangano; F Belardelli; C Perno; S Aquaro Journal: Clin Exp Immunol Date: 2009-01 Impact factor: 4.330
Authors: Alonso Heredia; Bruce Gilliam; Olga Latinovic; Nhut Le; Douty Bamba; Anthony Devico; Gregory B Melikyan; Robert C Gallo; Robert R Redfield Journal: Antimicrob Agents Chemother Date: 2007-05-07 Impact factor: 5.191